PuraPharm Corporation Limited (1498.HK)
HKD 0.55
(-3.51%)
HKD 0.55
(-3.51%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 216.62 Million HKD | -17.55% |
| 2022 | 260.58 Million HKD | -38.23% |
| 2021 | 421.85 Million HKD | 14.42% |
| 2020 | 368.68 Million HKD | -7.27% |
| 2019 | 397.59 Million HKD | -12.6% |
| 2018 | 454.9 Million HKD | 14.91% |
| 2017 | 395.85 Million HKD | 13.49% |
| 2016 | 348.8 Million HKD | 14.09% |
| 2015 | 305.73 Million HKD | 31.72% |
| 2014 | 232.11 Million HKD | 5.88% |
| 2013 | 219.21 Million HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 113.26 Million HKD | 8.79% |
| 2023 Q2 | 110.73 Million HKD | -0.58% |
| 2023 FY | 214.84 Million HKD | -17.55% |
| 2023 Q4 | 104.1 Million HKD | -5.99% |
| 2022 FY | 260.58 Million HKD | -38.23% |
| 2022 Q4 | 111.38 Million HKD | -25.35% |
| 2022 Q2 | 149.2 Million HKD | -34.06% |
| 2021 Q2 | 195.59 Million HKD | -4.35% |
| 2021 FY | 421.85 Million HKD | 14.42% |
| 2021 Q4 | 226.25 Million HKD | 15.68% |
| 2020 Q2 | 164.2 Million HKD | -19.96% |
| 2020 FY | 368.68 Million HKD | -7.27% |
| 2020 Q4 | 204.48 Million HKD | 24.53% |
| 2019 FY | 397.59 Million HKD | -12.6% |
| 2019 Q2 | 192.44 Million HKD | -11.96% |
| 2019 Q4 | 205.14 Million HKD | 6.6% |
| 2018 FY | 454.9 Million HKD | 14.91% |
| 2018 Q4 | 218.58 Million HKD | -7.5% |
| 2018 Q2 | 236.31 Million HKD | 9.92% |
| 2017 Q2 | 180.86 Million HKD | -12.71% |
| 2017 Q4 | 214.99 Million HKD | 18.87% |
| 2017 FY | 395.85 Million HKD | 13.49% |
| 2016 FY | 348.8 Million HKD | 14.09% |
| 2016 Q2 | 141.6 Million HKD | -24.17% |
| 2016 Q4 | 207.19 Million HKD | 46.32% |
| 2015 Q2 | 119 Million HKD | -10.97% |
| 2015 FY | 305.73 Million HKD | 31.72% |
| 2015 Q4 | 186.73 Million HKD | 56.92% |
| 2014 Q4 | 133.67 Million HKD | 35.79% |
| 2014 FY | 232.11 Million HKD | 5.88% |
| 2014 Q2 | 98.44 Million HKD | 69.64% |
| 2013 FY | 219.21 Million HKD | 0.0% |
| 2013 Q4 | 58.02 Million HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -29.38% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 96.68% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -652.733% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | 45.131% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 708.457% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 60.707% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 85.927% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 54.035% |
| SSY Group Limited | 3.48 Billion HKD | 93.791% |
| JBM (Healthcare) Limited | 319.41 Million HKD | 32.18% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 65.087% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 99.5% |